Compare OOMA & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | BNR |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.9M | 318.2M |
| IPO Year | 2015 | 2019 |
| Metric | OOMA | BNR |
|---|---|---|
| Price | $11.49 | $29.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 131.2K | 11.9K |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $114,490,000.00 | N/A |
| Revenue This Year | $7.80 | $136.32 |
| Revenue Next Year | $19.21 | N/A |
| P/E Ratio | $128.67 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $2.18 |
| 52 Week High | $15.09 | $41.72 |
| Indicator | OOMA | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 49.74 |
| Support Level | $11.28 | $28.28 |
| Resistance Level | $11.80 | $34.26 |
| Average True Range (ATR) | 0.44 | 2.86 |
| MACD | -0.04 | -1.00 |
| Stochastic Oscillator | 45.45 | 13.37 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.